{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T12:17:50Z","timestamp":1783772270570,"version":"3.55.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373246"],"award-info":[{"award-number":["82373246"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ijbiomac.2025.149135","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T16:14:45Z","timestamp":1763655285000},"page":"149135","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"P2","title":["PD-L1 splice variant-driven soluble PD-L1 secretion promotes immune evasion in gastric cancer"],"prefix":"10.1016","volume":"334","author":[{"given":"Kecheng","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinxiao","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ijbiomac.2025.149135_bb0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.149135_bb0010","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-023-01451-3","article-title":"Gastric cancer treatment: recent progress and future perspectives","volume":"16","author":"Guan","year":"2023","journal-title":"J. Hematol. Oncol."},{"issue":"10","key":"10.1016\/j.ijbiomac.2025.149135_bb0015","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2020.3370","article-title":"Efficacy and safety of Pembrolizumab or Pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer","volume":"6","author":"Shitara","year":"2020","journal-title":"JAMA Oncol."},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.149135_bb0020","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1007\/s10120-021-01173-w","article-title":"Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab","volume":"24","author":"Boku","year":"2021","journal-title":"Gastric Cancer"},{"issue":"7890","key":"10.1016\/j.ijbiomac.2025.149135_bb0025","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41586-021-04161-3","article-title":"The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer","volume":"600","author":"Janjigian","year":"2021","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.149135_bb0030","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41568-021-00431-4","article-title":"Programmed death ligand 1 signals in cancer cells","volume":"22","author":"Kornepati","year":"2022","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.149135_bb0035","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","article-title":"PD-L1 expression as a predictive biomarker in cancer immunotherapy","volume":"14","author":"Patel","year":"2015","journal-title":"Mol. Cancer Ther."},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.149135_bb0040","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1158\/2326-6066.CIR-16-0329","article-title":"Soluble PD-L1 as a biomarker in malignant melanoma treated with checkpoint blockade","volume":"5","author":"Zhou","year":"2017","journal-title":"Cancer Immunol. Res."},{"issue":"7718","key":"10.1016\/j.ijbiomac.2025.149135_bb0045","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s41586-018-0392-8","article-title":"Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response","volume":"560","author":"Chen","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.ijbiomac.2025.149135_bb0050","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.827921","article-title":"Biological characteristics and clinical significance of soluble PD-1\/PD-L1 and exosomal PD-L1 in cancer","volume":"13","author":"Niu","year":"2022","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.149135_bb0055","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003527","article-title":"Soluble PD-L1 as an early marker of progressive disease on nivolumab","volume":"10","author":"Mahoney","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.149135_bb0060","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.153323","article-title":"Soluble PD-L1 works as a decoy in lung cancer immunotherapy via alternative polyadenylation","volume":"7","author":"Sagawa","year":"2022","journal-title":"JCI Insight"},{"issue":"8","key":"10.1016\/j.ijbiomac.2025.149135_bb0065","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s00432-016-2184-6","article-title":"Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer","volume":"142","author":"Takahashi","year":"2016","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.149135_bb0070","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1084\/jem.20180870","article-title":"Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non\u2013small cell lung cancer","volume":"216","author":"Gong","year":"2019","journal-title":"J. Exp. Med."},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.149135_bb0075","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1007\/s10120-023-01429-7","article-title":"Soluble PD-L1 as a diagnostic and prognostic biomarker in resectable gastric cancer patients","volume":"26","author":"Chivu-Economescu","year":"2023","journal-title":"Gastric Cancer"},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.149135_bb0080","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1245\/s10434-018-07112-x","article-title":"Soluble PD-L1 expression in circulation as a predictive marker for recurrence and prognosis in gastric cancer: direct comparison of the clinical burden between tissue and serum PD-L1 expression","volume":"26","author":"Shigemori","year":"2019","journal-title":"Ann. Surg. Oncol."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.149135_bb0085","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.immuni.2018.03.014","article-title":"Regulation and function of the PD-L1 checkpoint","volume":"48","author":"Sun","year":"2018","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.149135_bb0090","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1744980","article-title":"ADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L)1 inhibitor resistance","volume":"9","author":"Orme","year":"2020","journal-title":"OncoImmunology"},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.149135_bb0095","article-title":"Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF-\u03baB","volume":"10","author":"Cheriyath","year":"2015","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.ijbiomac.2025.149135_bb0100","doi-asserted-by":"crossref","first-page":"4065","DOI":"10.1007\/s00262-023-03543-y","article-title":"An alternatively spliced PD-L1 isoform PD-L1\u22063, and PD-L2 expression in breast cancers: implications for eligibility scoring and immunotherapy response","volume":"72","author":"Dioken","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.149135_bb0105","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00262-018-2282-1","article-title":"A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression","volume":"68","author":"Mahoney","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.149135_bb0110","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s00262-018-2284-z","article-title":"Identification and characterization of an alternative cancer-derived PD-L1 splice variant","volume":"68","author":"Hassounah","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.149135_bb0115","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-023-01900-0","article-title":"Acidosis-mediated increase in IFN-\u03b3-induced PD-L1 expression on cancer cells as an immune escape mechanism in solid tumors","volume":"22","author":"Knopf","year":"2023","journal-title":"Mol. Cancer"},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.149135_bb0120","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.3892\/ol.2020.11757","article-title":"Interferon-\u03b3 induced PD-L1 expression and soluble PD-L1 production in gastric cancer","volume":"20","author":"Imai","year":"2020","journal-title":"Oncol. Lett."},{"issue":"12","key":"10.1016\/j.ijbiomac.2025.149135_bb0125","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13123034","article-title":"Soluble programmed death ligand-1 (sPD-L1): a pool of circulating proteins implicated in health and diseases","volume":"13","author":"Bailly","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.149135_bb0130","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-018-0449-0","article-title":"Soluble immune checkpoints in cancer: production, function and biological significance","volume":"6","author":"Gu","year":"2018","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.149135_bb0135","doi-asserted-by":"crossref","first-page":"199","DOI":"10.4143\/crt.2020.497","article-title":"Prognostic value of serum soluble programmed death-ligand 1 and dynamics during chemotherapy in advanced gastric cancer patients","volume":"53","author":"Park","year":"2021","journal-title":"Cancer Res. Treat."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.149135_bb0140","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1245\/s10434-018-07112-x","article-title":"Soluble PD-L1 expression in circulation as a predictive marker for recurrence and prognosis in gastric cancer: direct comparison of the clinical burden between tissue and serum PD-L1 expression","volume":"26","author":"Shigemori","year":"2018","journal-title":"Ann. Surg. Oncol."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.149135_bb0145","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines13020500","article-title":"Assessing the clinical relevance of soluble PD-1 and PD-L1: a multi-cohort study across diverse tumor types and prognostic implications","volume":"13","author":"Kushlinskii","year":"2025","journal-title":"Biomedicines"},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.149135_bb0150","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/ags3.12175","article-title":"Is high serum programmed death ligand 1 level a risk factor for poor survival in patients with gastric cancer?","volume":"2","author":"Ito","year":"2018","journal-title":"Ann. Gastroenterol. Surg."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.149135_bb0155","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-57865-9","article-title":"Plasma exchange and radiation resensitize immunotherapy-refractory melanoma: a phase I trial","volume":"16","author":"Orme","year":"2025","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.149135_bb0160","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001113","article-title":"Therapeutic plasma exchange clears circulating soluble PD-L1 and PD-L1-positive extracellular vesicles","volume":"8","author":"Orme","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.149135_bb0165","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1091146","article-title":"A novel regulation of PD-1 ligands on mesenchymal stromal cells through MMP-mediated proteolytic cleavage","volume":"5","author":"Dezutter-Dambuyant","year":"2015","journal-title":"Oncoimmunology"},{"issue":"1\u20132","key":"10.1016\/j.ijbiomac.2025.149135_bb0170","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.imlet.2011.11.001","article-title":"Soluble B7-H1: differences in production between dendritic cells and T cells","volume":"142","author":"Frigola","year":"2012","journal-title":"Immunol. Lett."},{"issue":"7","key":"10.1016\/j.ijbiomac.2025.149135_bb0175","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.trecan.2024.03.008","article-title":"Gastric cancer immunosuppressive microenvironment heterogeneity: implications for therapy development","volume":"10","author":"Yasuda","year":"2024","journal-title":"Trends Cancer"},{"issue":"10251","key":"10.1016\/j.ijbiomac.2025.149135_bb0180","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","article-title":"Gastric cancer","volume":"396","author":"Smyth","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ijbiomac.2025.149135_bb0185","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.canlet.2019.01.016","article-title":"High-affinity human programmed death-1 ligand-1 variant promotes redirected T cells to kill tumor cells","volume":"447","author":"Liang","year":"2019","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.149135_bb0190","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S1470-2045(23)00541-7","article-title":"Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study","volume":"25","author":"Shitara","year":"2024","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.ijbiomac.2025.149135_bb0195","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.149135_bb0200","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41575-022-00703-w","article-title":"Current developments in gastric cancer: from molecular profiling to treatment strategy","volume":"20","author":"Alsina","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.149135_bb0205","article-title":"Alternative splicing and cancer: a systematic review","volume":"6","author":"Zhang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.149135_bb0210","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.molcel.2019.09.017","article-title":"Alternative splicing regulatory networks: functions, mechanisms, and evolution","volume":"76","author":"Ule","year":"2019","journal-title":"Mol. Cell"},{"issue":"9","key":"10.1016\/j.ijbiomac.2025.149135_bb0215","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.tcb.2020.06.003","article-title":"The roles of CD8+ T cell subsets in antitumor immunity","volume":"30","author":"St. Paul","year":"2020","journal-title":"Trends Cell Biol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.149135_bb0220","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-22173-5","article-title":"The folate cycle enzyme MTHFD2 induces cancer immune evasion through PD-L1 up-regulation","volume":"12","author":"Shang","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ijbiomac.2025.149135_bb0225","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.cytogfr.2016.07.005","article-title":"The untold story of IFN-\u03b3 in cancer biology","volume":"31","author":"Kursunel","year":"2016","journal-title":"Cytokine Growth Factor Rev."}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813025096928?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813025096928?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T08:51:35Z","timestamp":1781167895000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813025096928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":45,"alternative-id":["S0141813025096928"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.149135","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PD-L1 splice variant-driven soluble PD-L1 secretion promotes immune evasion in gastric cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.149135","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"149135"}}